Abnormal expansion of PD-1+ T lymphocytes may be a sign of lupus nephritis onset in patients with SLE. Elevated PD-1+CD4+ T cells represent an independent risk factor for lupus nephritis (LN) and may ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
Elevated baseline CTC counts are linked to worse overall survival, progression-free survival, and treatment response in cancer patients. In prostate cancer, patients with five or more CTCs at ...
While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results